Werewolf Therapeutics, Inc. — Investor Relations & Filings
Werewolf Therapeutics, Inc. is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company utilizes its proprietary PREDATOR® protein engineering platform to create a novel class of conditionally activated proinflammatory immune modulators, known as INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become selectively activated within the tumor microenvironment. This approach aims to generate a potent, localized anti-tumor immune response while minimizing the systemic side effects associated with conventional immunotherapies. The company's pipeline includes clinical-stage candidates such as WTX-124 and WTX-330.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-K - Werewolf Therapeutics, Inc. (0001785530) (Filer) | 2026-03-27 | English | |
| 8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer) | 2026-03-27 | English | |
| 8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer) | 2026-02-24 | English | |
| 8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer) | 2026-02-13 | English | |
| SCHEDULE 13G/A Filing | 2026-02-11 | English | |
| 8-K Filing | 2026-02-06 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 33058433 | 10-K - Werewolf Therapeutics, Inc. (0001785530) (Filer) | 2026-03-27 | English | ||
| 33058414 | 8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer) | 2026-03-27 | English | ||
| 32898233 | 8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer) | 2026-02-24 | English | ||
| 32898234 | 8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer) | 2026-02-13 | English | ||
| 31705258 | SCHEDULE 13G/A Filing | 2026-02-11 | English | ||
| 31705271 | 8-K Filing | 2026-02-06 | English | ||
| 13198047 | Director's Dealing 2026 | 2026-01-20 | English | ||
| 13198048 | Major Shareholding Notification 2026 | 2026-01-16 | English | ||
| 13198049 | Director's Dealing 2026 | 2026-01-15 | English | ||
| 13198050 | Director's Dealing 2026 | 2026-01-12 | English | ||
| 13198051 | Director's Dealing 2026 | 2026-01-07 | English | ||
| 13198052 | Regulatory Filings 2026 | 2026-01-06 | English | ||
| 13198053 | Regulatory Filings 2026 | 2026-01-06 | English | ||
| 13198054 | Regulatory Filings 2026 | 2026-01-06 | English | ||
| 13198055 | Regulatory Filings 2026 | 2026-01-06 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Coeptis Therapeutics Holdings, Inc.
Biopharmaceutical company developing cell therapy platforms…
|
COEP | US | Manufacturing |
|
Cogent Biosciences, Inc.
A clinical-stage biotech company developing precision thera…
|
COGT | US | Manufacturing |
|
Cohance Lifesciences Limited
Global CDMO and API platform offering end-to-end solutions …
|
COHANCE | IN | Manufacturing |
|
Coherus Oncology, Inc.
Biopharmaceutical company developing and commercializing im…
|
CHRS | US | Manufacturing |
|
Colinz Laboratories ltd.
Manufactures and markets medicinal formulations across dive…
|
531210 | IN | Manufacturing |
|
COLLEGIUM PHARMACEUTICAL, INC
A biopharmaceutical company developing abuse-deterrent pain…
|
COLL | US | Manufacturing |
|
CollPlant Biotechnologies Ltd
Develops plant-derived collagen for 3D bioprinting of tissu…
|
CLGN | US | Manufacturing |
|
COMPASS Pathways plc
Develops psilocybin treatments for difficult-to-treat menta…
|
CMPS | GB | Manufacturing |
|
Compass Therapeutics, Inc.
Clinical-stage biopharma developing antibody-based therapeu…
|
CMPX | US | Manufacturing |
|
Concord Biotech Limited
R&D-driven producer of fermentation-based APIs and formulat…
|
CONCORDBIO | IN | Manufacturing |
Werewolf Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34192/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34192 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34192 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34192 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34192}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Werewolf Therapeutics, Inc. (id: 34192)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.